Cutaneous T-Cell Lymphoma Global Market Report 2025

The cutaneous T-cell lymphoma market size has grown strongly in recent years. It will grow from $2.54 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period was driven by the rising incidence of cutaneous T-cell lymphoma, increased awareness of rare cancers, a growing geriatric population, the availability of targeted therapies, and improvements in supportive care.

The cutaneous T-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $3.57 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth during the forecast period is driven by rising healthcare expenditure, a greater focus on orphan drug development, advancements in diagnostic capabilities, expanding patient support initiatives, and an increase in combination therapy approvals. Key trends include the shift toward personalized medicine, the emergence of biosimilars, the expansion of clinical trials, growing collaborations among market players, and the increasing adoption of telemedicine platforms.

The increasing prevalence of lymphoma cases is expected to drive the growth of the cutaneous T-cell lymphoma market. Lymphoma is a type of cancer that originates in lymphocytes, a type of white blood cell found in the lymphatic system. The rising incidence of lymphoma is linked to factors such as aging populations, environmental exposures, and genetic predispositions. Cutaneous T-cell lymphoma plays a crucial role in managing lymphoma cases by offering a specialized diagnosis and treatment approach for patients whose lymphoma primarily affects the skin, setting it apart from other lymphoma types and guiding targeted therapies. For example, in April 2024, an article published by the American Cancer Society, a US-based nonprofit organization dedicated to cancer research and advocacy, reported that in 2022, there were approximately 553,000 newly diagnosed cases of non-Hodgkin lymphoma and 250,000 related deaths, along with 84,000 new cases of Hodgkin lymphoma and 22,000 associated fatalities. Non-Hodgkin lymphoma ranks as the 10th most commonly diagnosed cancer and the 11th leading cause of cancer-related mortality worldwide. As a result, the increasing burden of lymphoma cases is fueling the expansion of the cutaneous T-cell lymphoma market.

Leading companies in the cutaneous T-cell lymphoma market are focusing on developing advanced treatments, such as targeted mechanisms of action that simultaneously address both malignant T-cells and immunosuppressive regulatory T-cells (Tregs), providing a competitive advantage. This dual-targeting approach enables LYMPHIR to not only eliminate tumor cells directly but also temporarily deplete Tregs, potentially enhancing the body's immune response against tumors. For instance, in August 2024, a US-based pharmaceutical company received FDA approval for LYMPHIR (denileukin diftitox-cxdl), marking a significant breakthrough in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). This innovative treatment approach differentiates LYMPHIR from existing therapies, offering a novel option for patients with relapsed or refractory CTCL.

In February 2022, Equillium, a US-based biotechnology company, acquired Bioniz Therapeutics for an undisclosed amount. This acquisition significantly strengthens Equillium’s immunology pipeline by integrating a diverse portfolio of first-in-class immuno-inflammatory drug candidates at various stages of development. Bioniz Therapeutics, a US-based company, specializes in treatments for cutaneous T-cell lymphoma, further expanding Equillium’s capabilities in the field of immunology and oncology.

Major players in the cutaneous T-cell lymphoma market are Merck & Co. Inc., Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bausch Health Companies Inc., Eisai Co. Ltd., Galderma S.A., Kyowa Hakko Kirin Co. Ltd., Cipla Inc., Actelion Pharmaceuticals Ltd., Soligenix Inc., Helsinn Healthcare SA, Innate Pharma SA, 4SC AG, Equillium Inc., Avik Pharma Inc., Citius Pharmaceuticals Inc., Medivir AB.

North America was the largest region in the cutaneous T-cell lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cutaneous T-cell lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cutaneous T-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cutaneous T-cell lymphoma is a rare form of cancer that affects the skin’s T-cells, causing symptoms such as rashes, tumors, and skin lesions. The most common subtypes are mycosis fungoides and Sézary syndrome, with symptoms including itching, skin thickening, and swollen lymph nodes. While the disease typically progresses slowly, advanced cases can spread to other organs.

The primary types of cutaneous T-cell lymphoma are mycosis fungoides and Sézary syndrome. Mycosis fungoides occurs when specific white blood cells, known as T cells, become cancerous and mainly impact the skin. Treatment options include radiation therapy, chemotherapy, immunotherapy, targeted therapy, and others, with these therapies being utilized across various healthcare settings such as hospitals, diagnostic centers, and clinics.

The cutaneous T-cell lymphoma market research report is one of a series of new reports that provides cutaneous T-cell lymphoma market statistics, including cutaneous T-cell lymphoma industry global market size, regional shares, competitors with a cutaneous T-cell lymphoma market share, detailed cutaneous T-cell lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous T-cell lymphoma industry. This cutaneous T-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cutaneous T-cell lymphoma market includes revenues earned by entities by providing services such as skin biopsies, imaging studies, and molecular and genetic testing and related products such as topical corticosteroids, topical retinoids, and monoclonal antibodies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.